These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

169 related items for PubMed ID: 14612098

  • 21.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients.
    Nair MP, Nampoory MR, Johny KV, Costandi JN, Abdulhalim M, El-Reshaid W, Al-Muzairai I, Ninan VT, Samhan M, Al-Mousawi M.
    Transplant Proc; 2001 Aug; 33(5):2767-9. PubMed ID: 11498153
    [No Abstract] [Full Text] [Related]

  • 24. A multicenter, open-label, comparative trial of two daclizumab dosing strategies versus no antibody induction in simultaneous kidney-pancreas transplantation: 6-month interim analysis.
    Stratta RJ, Alloway RR, Hodge E, Lo A, Pancreas Investigators Vital Outcomes Trial (PIVOT) Study Group.
    Transplant Proc; 2002 Aug; 34(5):1903-5. PubMed ID: 12176622
    [No Abstract] [Full Text] [Related]

  • 25. A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: a single-center experience.
    Soltero L, Carbajal H, Sarkissian N, Khan AJ, Brennan S, Gonzalez JM, Truong LD, Suki WN.
    Transplantation; 2004 Nov 27; 78(10):1560-3. PubMed ID: 15599323
    [Abstract] [Full Text] [Related]

  • 26. Daclizumab to prevent rejection after cardiac transplantation.
    Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.
    N Engl J Med; 2005 Jun 30; 352(26):2705-13. PubMed ID: 15987919
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. New therapeutic monoclonal antibodies target kidney transplant rejection and cancer.
    Piascik P.
    J Am Pharm Assoc (Wash); 1998 Jun 30; 38(3):379-80. PubMed ID: 9654869
    [No Abstract] [Full Text] [Related]

  • 29. Immunosuppressive [correction of immunosupressive] agents and their actions.
    First MR.
    Transplant Proc; 2002 Aug 30; 34(5):1369-71. PubMed ID: 12176401
    [No Abstract] [Full Text] [Related]

  • 30. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group.
    Vincenti F, Kirkman R, Light S, Bumgardner G, Pescovitz M, Halloran P, Neylan J, Wilkinson A, Ekberg H, Gaston R, Backman L, Burdick J.
    N Engl J Med; 1998 Jan 15; 338(3):161-5. PubMed ID: 9428817
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Daclizumab versus anti-thymocyte globulin-fresenius as induction therapy for low-risk kidney transplant recipients.
    Abou-Jaoude MM, Ghantous I, Najm R, Afif C, Almawi WY.
    Transplant Proc; 2003 Nov 15; 35(7):2731-2. PubMed ID: 14612096
    [No Abstract] [Full Text] [Related]

  • 33. Daclizumab: a review of its use in the prevention of acute rejection in renal transplant recipients.
    Wiseman LR, Faulds D.
    Drugs; 1999 Dec 15; 58(6):1029-42. PubMed ID: 10651389
    [Abstract] [Full Text] [Related]

  • 34. Can antibody prophylaxis allow sparing of other immunosuppressives?
    Vincenti F, Grinyo J, Ramos E, Nashan B, Stuart F, Kuypers D, Brattstrom C, Cho S, Ekberg H, Johnson R.
    Transplant Proc; 1999 Dec 15; 31(1-2):1246-8. PubMed ID: 10083557
    [No Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Could prophylactic monoclonal antibody improve kidney graft survival?
    Pourmand G, Saraji A, Salem S, Mehrsai A, Nikoobakht MR, Taherimahmoudi M, Rezaeidanesh M, Asadpour A.
    Transplant Proc; 2009 Sep 15; 41(7):2794-6. PubMed ID: 19765437
    [Abstract] [Full Text] [Related]

  • 40. [Anti interleukin-2 receptor alpha antibodies (daclizumab) application for the treatment of kidney recipients].
    Izvolskaja N, Rainiene T, Dainys B.
    Medicina (Kaunas); 2003 Sep 15; 39 Suppl 1():166-70. PubMed ID: 12761441
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.